Intramolecular Oxidoreductases
"Intramolecular Oxidoreductases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzymes of the isomerase class that catalyze the oxidation of one part of a molecule with a corresponding reduction of another part of the same molecule. They include enzymes converting aldoses to ketoses (ALDOSE-KETOSE ISOMERASES), enzymes shifting a carbon-carbon double bond (CARBON-CARBON DOUBLE BOND ISOMERASES), and enzymes transposing S-S bonds (SULFUR-SULFUR BOND ISOMERASES). (From Enzyme Nomenclature, 1992) EC 5.3.
| Descriptor ID |
D019746
|
| MeSH Number(s) |
D08.811.399.475
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Intramolecular Oxidoreductases".
Below are MeSH descriptors whose meaning is more specific than "Intramolecular Oxidoreductases".
This graph shows the total number of publications written about "Intramolecular Oxidoreductases" by people in this website by year, and whether "Intramolecular Oxidoreductases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 2 | 1 | 3 |
| 2001 | 1 | 0 | 1 |
| 2002 | 3 | 1 | 4 |
| 2003 | 2 | 1 | 3 |
| 2004 | 0 | 3 | 3 |
| 2005 | 2 | 2 | 4 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 2 | 4 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 4 | 4 |
| 2011 | 1 | 2 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 3 | 3 | 6 |
| 2014 | 2 | 2 | 4 |
| 2015 | 3 | 0 | 3 |
| 2016 | 0 | 1 | 1 |
| 2018 | 2 | 1 | 3 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Intramolecular Oxidoreductases" by people in Profiles.
-
MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK-ERK and AP-1 pathways. Carcinogenesis. 2024 Aug 12; 45(8):582-594.
-
Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion. Cancer Res Commun. 2023 07; 3(7):1397-1408.
-
Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma. Cell Death Dis. 2022 02 04; 13(2):117.
-
Engineering 'Enzymelink' for screening lead compounds to inhibit mPGES-1 while maintaining prostacyclin synthase activity. Future Med Chem. 2021 07; 13(13):1091-1103.
-
MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma. Oncoimmunology. 2020 12 06; 9(1):1846915.
-
MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma. Blood. 2020 11 26; 136(22):2557-2573.
-
Tuft Cells Inhibit Pancreatic Tumorigenesis in Mice by Producing Prostaglandin D2. Gastroenterology. 2020 11; 159(5):1866-1881.e8.
-
ZFPM2-AS1, a novel lncRNA, attenuates the p53 pathway and promotes gastric carcinogenesis by stabilizing MIF. Oncogene. 2018 11; 37(45):5982-5996.
-
Macrophage migration inhibitory factor (MIF) gene is associated with adolescents' cortisol reactivity and anxiety. Psychoneuroendocrinology. 2018 09; 95:170-178.
-
Creating a mouse model resistant to induced ischemic stroke and cardiovascular damage. Sci Rep. 2018 01 26; 8(1):1653.